Cargando…

Mannose-modified erythrocyte membrane-encapsulated chitovanic nanoparticles as a DNA vaccine carrier against reticuloendothelial tissue hyperplasia virus

INTRODUCTION: The erythrocyte membranes used in nanovaccines include high membrane stability, long circulation life, adaptability and extremely good bio compatibility. Nanoparticles encapsulated by erythrocyte membranes are widely used as ideal drug delivery vehicles because of their high drug loadi...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Yangyang, Tang, Feng, Li, Sheng, Wu, Daiyan, Liu, Qianqian, Li, Hangyu, Zhang, Xinnan, Liu, Ziwei, Zhang, Linzi, Feng, Haibo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910308/
https://www.ncbi.nlm.nih.gov/pubmed/36776397
http://dx.doi.org/10.3389/fimmu.2022.1066268
_version_ 1784884759148625920
author Feng, Yangyang
Tang, Feng
Li, Sheng
Wu, Daiyan
Liu, Qianqian
Li, Hangyu
Zhang, Xinnan
Liu, Ziwei
Zhang, Linzi
Feng, Haibo
author_facet Feng, Yangyang
Tang, Feng
Li, Sheng
Wu, Daiyan
Liu, Qianqian
Li, Hangyu
Zhang, Xinnan
Liu, Ziwei
Zhang, Linzi
Feng, Haibo
author_sort Feng, Yangyang
collection PubMed
description INTRODUCTION: The erythrocyte membranes used in nanovaccines include high membrane stability, long circulation life, adaptability and extremely good bio compatibility. Nanoparticles encapsulated by erythrocyte membranes are widely used as ideal drug delivery vehicles because of their high drug loading, long circulation time, and excellent biocompatibility. The mannose modification of delivery materials can help target mannose receptors (MRs) to deliver antigens to antigen-presenting cells (APCs). METHODS: In this study, the antigen gene gp90 of avian reticuloendotheliosis virus (REV) was encapsulated with carboxymethyl chitosan (CS) to obtain CSgp90 nanoparticles, which were coated with mannose-modied fowl erythrocyte membranes to yield CS-gp90@M-M nanoparticles. The physicochemical characterization and immune response of the CS-gp90@M-M nanoparticles were investigated in vitro and in vivo. RESULTS: CS-gp90@M-M nanoparticles were rapidly phagocytized in vitro by macrophages to induce the production of cytokines and nitric oxide. In vivo, CS-gp90@M-M nanoparticles increased cytokine levels, the CD4+/8+ ratio, REV-specific antibodies in the peripheral blood of chicks, and the mRNA levels of immune-related genes in the spleen and bursa of immunized chicks. CS-gp90@M-M nanoparticles could be targeted to lymphoid organs to prolong the retention time of the nanoparticles at the injection site and lymphatic organs, leading to a strong, sustained immune response. Moreover, the CS-gp90@M-M nano-vaccine showed a lasting immunoprotective effect and improved the body weight of chicks after the challenge. CONCLUSION: Overall, CS-gp90@M-M nanoparticles can be used in vaccine designs as an effective delivery carrier with immune response-enhancing effects.
format Online
Article
Text
id pubmed-9910308
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99103082023-02-10 Mannose-modified erythrocyte membrane-encapsulated chitovanic nanoparticles as a DNA vaccine carrier against reticuloendothelial tissue hyperplasia virus Feng, Yangyang Tang, Feng Li, Sheng Wu, Daiyan Liu, Qianqian Li, Hangyu Zhang, Xinnan Liu, Ziwei Zhang, Linzi Feng, Haibo Front Immunol Immunology INTRODUCTION: The erythrocyte membranes used in nanovaccines include high membrane stability, long circulation life, adaptability and extremely good bio compatibility. Nanoparticles encapsulated by erythrocyte membranes are widely used as ideal drug delivery vehicles because of their high drug loading, long circulation time, and excellent biocompatibility. The mannose modification of delivery materials can help target mannose receptors (MRs) to deliver antigens to antigen-presenting cells (APCs). METHODS: In this study, the antigen gene gp90 of avian reticuloendotheliosis virus (REV) was encapsulated with carboxymethyl chitosan (CS) to obtain CSgp90 nanoparticles, which were coated with mannose-modied fowl erythrocyte membranes to yield CS-gp90@M-M nanoparticles. The physicochemical characterization and immune response of the CS-gp90@M-M nanoparticles were investigated in vitro and in vivo. RESULTS: CS-gp90@M-M nanoparticles were rapidly phagocytized in vitro by macrophages to induce the production of cytokines and nitric oxide. In vivo, CS-gp90@M-M nanoparticles increased cytokine levels, the CD4+/8+ ratio, REV-specific antibodies in the peripheral blood of chicks, and the mRNA levels of immune-related genes in the spleen and bursa of immunized chicks. CS-gp90@M-M nanoparticles could be targeted to lymphoid organs to prolong the retention time of the nanoparticles at the injection site and lymphatic organs, leading to a strong, sustained immune response. Moreover, the CS-gp90@M-M nano-vaccine showed a lasting immunoprotective effect and improved the body weight of chicks after the challenge. CONCLUSION: Overall, CS-gp90@M-M nanoparticles can be used in vaccine designs as an effective delivery carrier with immune response-enhancing effects. Frontiers Media S.A. 2023-01-04 /pmc/articles/PMC9910308/ /pubmed/36776397 http://dx.doi.org/10.3389/fimmu.2022.1066268 Text en Copyright © 2023 Feng, Tang, Li, Wu, Liu, Li, Zhang, Liu, Zhang and Feng https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Feng, Yangyang
Tang, Feng
Li, Sheng
Wu, Daiyan
Liu, Qianqian
Li, Hangyu
Zhang, Xinnan
Liu, Ziwei
Zhang, Linzi
Feng, Haibo
Mannose-modified erythrocyte membrane-encapsulated chitovanic nanoparticles as a DNA vaccine carrier against reticuloendothelial tissue hyperplasia virus
title Mannose-modified erythrocyte membrane-encapsulated chitovanic nanoparticles as a DNA vaccine carrier against reticuloendothelial tissue hyperplasia virus
title_full Mannose-modified erythrocyte membrane-encapsulated chitovanic nanoparticles as a DNA vaccine carrier against reticuloendothelial tissue hyperplasia virus
title_fullStr Mannose-modified erythrocyte membrane-encapsulated chitovanic nanoparticles as a DNA vaccine carrier against reticuloendothelial tissue hyperplasia virus
title_full_unstemmed Mannose-modified erythrocyte membrane-encapsulated chitovanic nanoparticles as a DNA vaccine carrier against reticuloendothelial tissue hyperplasia virus
title_short Mannose-modified erythrocyte membrane-encapsulated chitovanic nanoparticles as a DNA vaccine carrier against reticuloendothelial tissue hyperplasia virus
title_sort mannose-modified erythrocyte membrane-encapsulated chitovanic nanoparticles as a dna vaccine carrier against reticuloendothelial tissue hyperplasia virus
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910308/
https://www.ncbi.nlm.nih.gov/pubmed/36776397
http://dx.doi.org/10.3389/fimmu.2022.1066268
work_keys_str_mv AT fengyangyang mannosemodifiederythrocytemembraneencapsulatedchitovanicnanoparticlesasadnavaccinecarrieragainstreticuloendothelialtissuehyperplasiavirus
AT tangfeng mannosemodifiederythrocytemembraneencapsulatedchitovanicnanoparticlesasadnavaccinecarrieragainstreticuloendothelialtissuehyperplasiavirus
AT lisheng mannosemodifiederythrocytemembraneencapsulatedchitovanicnanoparticlesasadnavaccinecarrieragainstreticuloendothelialtissuehyperplasiavirus
AT wudaiyan mannosemodifiederythrocytemembraneencapsulatedchitovanicnanoparticlesasadnavaccinecarrieragainstreticuloendothelialtissuehyperplasiavirus
AT liuqianqian mannosemodifiederythrocytemembraneencapsulatedchitovanicnanoparticlesasadnavaccinecarrieragainstreticuloendothelialtissuehyperplasiavirus
AT lihangyu mannosemodifiederythrocytemembraneencapsulatedchitovanicnanoparticlesasadnavaccinecarrieragainstreticuloendothelialtissuehyperplasiavirus
AT zhangxinnan mannosemodifiederythrocytemembraneencapsulatedchitovanicnanoparticlesasadnavaccinecarrieragainstreticuloendothelialtissuehyperplasiavirus
AT liuziwei mannosemodifiederythrocytemembraneencapsulatedchitovanicnanoparticlesasadnavaccinecarrieragainstreticuloendothelialtissuehyperplasiavirus
AT zhanglinzi mannosemodifiederythrocytemembraneencapsulatedchitovanicnanoparticlesasadnavaccinecarrieragainstreticuloendothelialtissuehyperplasiavirus
AT fenghaibo mannosemodifiederythrocytemembraneencapsulatedchitovanicnanoparticlesasadnavaccinecarrieragainstreticuloendothelialtissuehyperplasiavirus